Neurotype Inc. Company Profile

Background

Mission and Vision

Neurotype Inc. is dedicated to revolutionizing the treatment of Substance Use Disorders (SUD) by providing personalized brain interventions that effectively address triggers and cravings. The company's mission is to enable transformative addiction treatment through advanced neuroscience and personalized medicine. Founded by Dr. Scott Burwell, Neurotype aims to bridge the gap between laboratory research and clinical application, offering innovative solutions for addiction recovery.

Primary Area of Focus and Industry Significance

Specializing in the development of neurotechnology-based solutions, Neurotype focuses on creating objective, data-driven tools to monitor and manage addiction triggers. Their flagship product, the NeuromarkR™ platform, utilizes non-invasive EEG sensors to measure brain responses to drug-related cues, providing clinicians with quantitative insights to tailor interventions. This approach represents a significant advancement in addiction treatment, moving beyond traditional subjective assessments to evidence-based, personalized care.

Key Strategic Focus

Core Objectives

Neurotype's strategic focus centers on developing and commercializing the NeuromarkR™ platform, aiming to:

• Objective Measurement of Craving: Utilize EEG-based sensors to provide clinicians with real-time, objective data on patients' brain responses to addiction triggers.

• Personalized Treatment Plans: Enable the creation of tailored therapeutic interventions based on individual brain activity patterns, enhancing treatment efficacy.

• Integration with Existing Therapies: Complement traditional psychological, pharmacological, and neuromodulation treatments by offering a measurement-based approach that addresses the neurobiological aspects of addiction.

Specific Areas of Specialization

Neurotype specializes in:

• Neurotechnology Development: Designing and refining EEG-based devices and software platforms for addiction treatment.

• Biomarker Identification: Identifying and validating brain-based biomarkers associated with craving and relapse.

• Clinical Integration: Ensuring seamless incorporation of their technology into clinical settings to enhance treatment outcomes.

Key Technologies Utilized

The company employs:

• EEG Sensors: For non-invasive monitoring of brain activity.

• Neurofeedback Mechanisms: To provide real-time feedback to patients, facilitating neuroplastic changes.

• Data Analytics Software: For processing and interpreting complex neural data to inform clinical decisions.

Primary Markets Targeted

Neurotype primarily targets:

• Addiction Treatment Centers: Seeking advanced tools for managing relapse triggers.

• Mental Health Clinics: Looking to integrate neurotechnology into their therapeutic offerings.

• Research Institutions: Interested in studying the neurobiological underpinnings of addiction.

Financials and Funding

Funding History

Neurotype Inc. has secured a total of $1.17 million in funding through multiple rounds, including:

• National Institute on Drug Abuse (NIDA): Provided significant support, including a $327,000 seed funding round.

• National Institutes of Health (NIH): Offered additional grants to support the development of their technology.

• Yale University: Recognized the company's innovation with a first prize at Yale’s 2019 Innovation to Impact in SUD week.

Utilization of Capital

The raised capital is allocated towards:

• Product Development: Advancing the NeuromarkR™ platform through research and refinement.

• Clinical Trials: Conducting studies to validate the efficacy of their technology in real-world settings.

• Regulatory Compliance: Ensuring the product meets FDA standards for medical devices.

Pipeline Development

Key Pipeline Candidates

Neurotype's primary focus is on the NeuromarkR™ platform, which is in the following stages:

• Clinical Trials: Ongoing studies to assess the device's effectiveness in monitoring and managing addiction triggers.

• Regulatory Approval: Preparation for FDA submission to obtain clearance for clinical use.

Target Conditions

The platform is designed to address:

• Substance Use Disorders: Including alcohol, opioid, and other drug dependencies.

• Food Addictions: By monitoring brain responses to food-related cues.

Anticipated Milestones

• Clinical Validation: Expected within the next 12-18 months, pending trial outcomes.

• Regulatory Submission: Planned for the following 6 months, contingent on clinical trial results.

Technological Platform and Innovation

Proprietary Technologies

Neurotype's NeuromarkR™ platform integrates:

• EEG-Based Sensors: For capturing real-time brain activity data.

• Neurofeedback Systems: To provide patients with immediate feedback, promoting neural adaptation.

• Data Analytics Software: For processing and interpreting complex neural data to inform clinical decisions.

Significant Scientific Methods

The company employs:

• Visual Evoked Potentials (VEPs): To measure brain responses to addiction-related cues.

• Attention Bias Modification (ABM): A therapeutic approach integrated into their platform to train patients away from drug-related cues.

Leadership Team

Scott Burwell, PhD – CEO

Dr. Burwell founded Neurotype Inc. in 2019, bringing over 15 years of research experience in addiction and brain sciences. His vision is to translate laboratory findings into practical, personalized treatment tools for addiction.

Competitor Profile

Market Insights and Dynamics

The addiction treatment market is evolving, with a growing emphasis on personalized and data-driven approaches. The integration of neurotechnology into addiction therapy is a burgeoning field, offering significant growth potential.

Competitor Analysis

Key competitors include:

• Neuronetics, Inc.: Specializes in non-invasive neuromodulation therapies for psychiatric and neurological disorders.

• Medtronic: Offers a range of neuromodulation devices for chronic pain and other conditions.

• Saluda Medical: Developing closed-loop spinal cord stimulation systems for chronic pain management.

Strategic Collaborations and Partnerships

Neurotype has established partnerships with:

• National Institute on Drug Abuse (NIDA): Providing funding and support for research and development.

• National Institutes of Health (NIH): Offering grants to advance their technology.

• Yale University: Recognizing their innovation in addiction treatment.

Operational Insights

Neurotype differentiates itself through:

• Objective Measurement: Providing real-time, data-driven insights into addiction triggers.

• Personalized Treatment: Enabling tailored therapeutic interventions based on individual brain activity patterns.

• Integration with Existing Therapies: Complementing traditional treatment modalities with advanced neurotechnology.

Strategic Opportunities and Future Directions

Neurotype plans to:

• Expand Clinical Applications: Adapt their platform for various addiction types and mental health conditions.

• Enhance Regulatory Compliance: Achieve FDA clearance for broader clinical use.

• Increase Market Penetration: Collaborate with more addiction treatment centers and mental health clinics.

Contact Information

Website: Neurotype.io

Social Media:

• Twitter: @neurotypeinc

• LinkedIn: Neurotype Inc.